Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

By L. Gattinoni, C. Klebanoff, D. Palmer, Claudia Wrzesinski, Keith W. Kerstann, Zhiya Yu, S. Finkelstein, M. Theoret, S. Rosenberg, N. Restifo. Journal of Clinical Investigation, 2005

992 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/f2785bdbe07a513627057d7739f0b9891f59ba98

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. S. Rosenberg
2. N. Restifo
3. James P. Allison
4. M. Dudley
5. S. Formenti
6. S. Demaria
7. C. June
8. Jie Yang

In Oncology

1. S. Rosenberg
2. N. Restifo
3. C. June
4. James P. Allison
5. M. Dudley
6. S. Formenti
7. S. Demaria
8. Jie Yang

Citations in the corpus

• Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts (2010, background): “…strategies are all complicated by ex vivo manipulations and complex mixtures of cytokines and growth factors required to prevent their terminal differentiation, and to allow them to maintain a pool of effector and memory tumor-reactive T cells after transfer in vivo (Gattinoni et al., 2005b, 2009).”
• Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. (2013, positive): “Studies in both tumor (46, 47) and chronic viral (48) models have demonstrated that CD8+ T cells with the capacity to home to secondary lymph nodes, where they can be”
• Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells (2009, background): “CD44 expression is known to increase with T cell differentiation, whereas CD62L expression is progressively los”
• Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells (2008, background): “In TDLN the CD8 CXCR6 cells may represent an early effector population (34).”
• Interleukin 12: still a promising candidate for tumor immunotherapy? (2014, background): “influences their differentiation, at least as far as the response against tumor-associated antigens is concerned [15,97].”
• A human memory T-cell subset with stem cell-like properties (2011, background): “T cell proliferative and survival capacities correlate with the antitumor efficacy of adoptively transferred T cell”
• Chimeric Receptor mRNA Transfection as a Tool to Generate Antineoplastic Lymphocytes (2008, positive): “Such extensive lymphocyte propagation transforms the majority of cells to the effector memory phenotype and may lead to insufficient antitumor activity in vivo (Dudley et al. , 2002; Gattinoni et al. , 2005; Cooper et al. , 2006).”
• Adoptive immunotherapy for cancer: harnessing the T cell response (2012, neutral): “Hem fare çalışmalarından hem de klinik deneylerden elde edilen gelişmekte olan bulgular, edinilmiş olarak transfer edilen T hücre popülasyonlarının farklılaşma evresine bağlı olan intrinsik özelliklerin ACT bazlı yaklaşımların başarısında önemli olduğunu göstermektedir (4,115,116).”
• Adoptive cell transfer: a clinical path to effective cancer immunotherapy (2008, background): “The characteristics of the transferred cells themselves had a profound effect: anti-tumour T cells with a CCR7 + , CD27 + , CD28 + , CD62L + phenotype that is characteristic of central memory cells were more effective than highly differentiated cells that lost these marker”